Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) who...
-
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of...
-
STEVENSON, Md., Feb. 15, 2018 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the...
-
OKLAHOMA CITY, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Federman & Sherwood announces that on February 14, 2018, a class action lawsuit was filed in the United States District Court for the Southern...
-
NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Ohr Pharmaceutical, Inc. (“Ohr” or the “Company”) (NASDAQ:OHRP)...
-
NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired...
-
NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today reported topline...
-
Management to Host a Conference Call and Webcast at 8:30 a.m. Eastern Time Today NEW YORK, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical...
-
NEW YORK, Oct. 11, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that...
-
NEW YORK, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today reported...